Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
IN

INVA

Market Closed

Innoviva, Inc.

NASDAQHealthcareBiotechnology
US
159 employees
CEO: Pavel Raifeld
Founded: 2004
$21.15
+$0.00(+NaN%)
Market Cap
1.56B
Beta
0.33
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $47.86, implying 127.1% upside from current levels. The stock appears significantly undervalued. Financial health scores indicate strong fundamentals (5.0/5). Monte Carlo analysis shows low downside risk (0% of scenarios below current price). Overall, this suggests a compelling buying opportunity at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore INVA

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

INVA in the Healthcare

Small Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →